Mylan N.V. (NASDAQ: MYL) is set to release its second-quarter financial results after the markets close on Tuesday. The consensus estimates from Thomson Reuters are calling for $1.14 in earnings per share (EPS) on $2.57 billion in revenue. Mylan posted EPS of $0.91 and $2.37 billion in revenue in the same period of last year.

This is an analyst favorite and it sports a very appealing valuation. Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals worldwide.

Like other major pharmaceutical companies, Mylan provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers, and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management and cardiovascular therapeutic areas.

Mylan had attempted a takeover of drugmaker Perrigo last year, which was fought off, and the company has since announced the purchase of Meda and recent acquisition of Renaissance. Some analysts love the company’s very attractive valuation, and trading at roughly 10 times estimated 2016 earnings per share, it clearly is cheap.

Ahead during the second quarter, a few analysts weighed in on Mylan:

• Morgan Stanley reiterated a Hold rating.
• JPMorgan reiterated an Overweight rating.
• Goldman Sachs has a Buy rating with a $60 price target.

Excluding Tuesday’s move, Mylan has underperformed the broad markets, with the stock down 10%. Over the past 52 weeks, the stock is down 14%, but in just the last quarter the stock is up 19%.

Shares of Mylan were trading up 3% at $50.10 on Tuesday, with a consensus analyst price target of $58.06 and a 52-week trading range of $37.59 to $57.77.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.